ChemoCentryx (NasdaqGS:CCXI) - Share price, News & Analysis

CCXI fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

CCXI Stock Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.

Rewards

Trading at 88.9% below our estimate of its fair value

Earnings are forecast to grow 70.86% per year

Risk Analysis

Shareholders have been diluted in the past year

ChemoCentryx Competitors

AbbVie

NYSE:ABBV

US$266.9b

Amgen

NasdaqGS:AMGN

US$132.2b

Biogen

NasdaqGS:BIIB

US$29.2b

Incyte

NasdaqGS:INCY

US$16.6b

Price History & Performance

Summary of all time highs, changes and price drops for ChemoCentryx
Historical stock prices
Current Share Price	US$22.79
52 Week High	US$42.16
52 Week Low	US$9.53
Beta	1.95
1 Month Change	17.11%
3 Month Change	-24.21%
1 Year Change	137.64%
3 Year Change	94.62%
5 Year Change	230.29%
Change since IPO	107.18%

Shareholder Returns

	CCXI	US Biotechs	US Market
7D	18.9%	1.4%	-2.7%
1Y	137.6%	-21.7%	-12.9%

Return vs Industry: CCXI exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: CCXI exceeded the US Market which returned -12.9% over the past year.

Price Volatility

Is CCXI's price volatile compared to industry and market?
CCXI volatility
CCXI Average Weekly Movement	12.2%
Biotechs Industry Average Movement	12.4%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	2.9%

Stable Share Price: CCXI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: CCXI's weekly volatility (12%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1996	178	Thomas Schall	https://www.chemocentryx.com

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis.

ChemoCentryx Fundamentals Summary

How do ChemoCentryx's earnings and revenue compare to its market cap?
CCXI fundamental statistics
Market Cap	US$1.62b
Earnings (TTM)	-US$140.65m
Revenue (TTM)	US$27.33m

59.4x

P/S Ratio

-11.5x

P/E Ratio

Is CCXI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
CCXI income statement (TTM)
Revenue	US$27.33m
Cost of Revenue	US$77.56m
Gross Profit	-US$50.22m
Other Expenses	US$90.43m
Earnings	-US$140.65m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.98
Gross Margin	-183.77%
Net Profit Margin	-514.64%
Debt/Equity Ratio	9.6%

How did CCXI perform over the long term?

See historical performance and comparison

Valuation

Is ChemoCentryx undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: CCXI ($22.79) is trading below our estimate of fair value ($205.39)

Significantly Below Fair Value: CCXI is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: CCXI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CCXI is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CCXI's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: CCXI is overvalued based on its PB Ratio (6.3x) compared to the US Biotechs industry average (1.5x).

Future Growth

How is ChemoCentryx forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

70.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CCXI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: CCXI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CCXI's is expected to become profitable in the next 3 years.

Revenue vs Market: CCXI's revenue (49.6% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: CCXI's revenue (49.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CCXI is forecast to be unprofitable in 3 years.

Past Performance

How has ChemoCentryx performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-45.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CCXI is currently unprofitable.

Growing Profit Margin: CCXI is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: CCXI is unprofitable, and losses have increased over the past 5 years at a rate of 45.3% per year.

Accelerating Growth: Unable to compare CCXI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CCXI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: CCXI has a negative Return on Equity (-54.36%), as it is currently unprofitable.

Financial Health

How is ChemoCentryx's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CCXI's short term assets ($351.6M) exceed its short term liabilities ($68.8M).

Long Term Liabilities: CCXI's short term assets ($351.6M) exceed its long term liabilities ($112.9M).

Debt to Equity History and Analysis

Debt Level: CCXI has more cash than its total debt.

Reducing Debt: Insufficient data to determine if CCXI's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CCXI has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CCXI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Dividend

What is ChemoCentryx current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CCXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CCXI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CCXI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CCXI's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CCXI has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure

CEO

Thomas Schall (62 yo)

25.5yrs

Tenure

US$8,978,084

Compensation

Dr. Thomas J. Schall, Ph.D. Founded ChemoCentryx Inc. in November 1996 and has been its Chief Executive Officer, President and Director since 1997. Dr. Schall focuses on the discovery and development of ch...

CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD8.98M) is above average for companies of similar size in the US market ($USD5.44M).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: CCXI's management team is considered experienced (2.8 years average tenure).

Board Members

Experienced Board: CCXI's board of directors are considered experienced (8.4 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/22 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31